Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Corenhanced Technologies LLC is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is split between 2 distinct examiners, which introduces a level of variety in the examination styles the company must address. Despite having multiple examiners, the company's matters are all contained within 1 distinct art unit. This suggests that while the individual reviewers differ, the technical classification and overarching policy environment remain consistent across the portfolio.
The busiest examiner for this entity is MERCIER, MELISSA S, who is currently handling 1 busiest examiner pending action. This specific action is part of the 2 pending office actions currently active for the company. The use of 2 distinct examiners within 1 distinct art unit allows the company to compare different examiner behaviors while remaining within the same technical guidelines of Biotechnology & Pharmaceuticals. This structure requires a strategy that can adapt to the specific nuances of MERCIER, MELISSA S while also managing the other pending matter under a different official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| NGUYEN, NGOC-ANH THI | 1 | 30.3% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554261 | COMPOSITIONS FOR SUPPLEMENTING PRODUCTS WITH THERAPEUTIC AGENTS AND METHODS OF USE THEREOF | MERCIER, MELISSA S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001089 | COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE AND MAKING THEREOF | NGUYEN, NGOC-ANH THI | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554261 | COMPOSITIONS FOR SUPPLEMENTING PRODUCTS WITH THERAPEUTIC AGENTS AND METHODS OF USE THEREOF | MERCIER, MELISSA S | 1615 | §102§103Other | Final Rejection | — | Pending | Oct 06, 2023 |
| 18001089 | COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE AND MAKING THEREOF | NGUYEN, NGOC-ANH THI | 1615 | §103 | Non-Final OA | — | Pending | Dec 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCorenhanced Technologies LLC has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Melissa S Mercier has the most, with 1 of Corenhanced Technologies LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
